Kymera Therapeutics, Inc. (KYMR)

Market Cap	2.09B
Revenue (ttm)	58.89M
Net Income (ttm)	-240.88M
Shares Out	65.12M
EPS (ttm)	-3.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	656,407
Open	31.37
Previous Close	30.07
Day's Range	30.51 - 33.71
52-Week Range	19.45 - 53.27
Beta	2.19
Analysts	Buy
Price Target	55.79 (+73.42%)
Earnings Date	May 9, 2025

About KYMR

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat aut...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 21, 2020
• Employees: 188
• Stock Exchange: NASDAQ
• Ticker Symbol: KYMR
• Website: https://www.kymeratx.com

Financial Performance

In 2024, Kymera Therapeutics's revenue was $47.07 million, a decrease of -40.11% compared to the previous year's $78.59 million. Losses were -$223.86 million, 52.3% more than in 2023.

Analyst Forecast

According to 14 analysts, the average rating for KYMR stock is "Buy." The 12-month stock price forecast is $55.79, which is an increase of 73.42% from the latest price.

Price Target

$55.79

(73.42% upside)

Analyst Consensus: Buy